Jonathan Young Sells 607 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 607 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $27,242.16. Following the completion of the transaction, the chief operating officer now directly owns 200,540 shares in the company, valued at $9,000,235.20. The trade was a 0.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jonathan Young also recently made the following trade(s):

• On Tuesday, March 4th, Jonathan Young sold 50,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.86, for a total value of $2,243,000.00.
• On Monday, February 3rd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $53.81, for a total value of $538,100.00.
• On Thursday, January 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $28.03, for a total value of $280,300.00.

Akero Therapeutics Stock Down 1.6 %

NASDAQ AKRO opened at $44.15 on Friday. The business has a fifty day moving average price of $42.10 and a two-hundred day moving average price of $33.84. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The stock has a market capitalization of $3.52 billion, a PE ratio of -11.77 and a beta of -0.19.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Equities analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new position in shares of Akero Therapeutics in the 4th quarter valued at $41,000. Sterling Capital Management LLC lifted its stake in shares of Akero Therapeutics by 764.3% in the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock valued at $50,000 after acquiring an additional 1,582 shares during the last quarter. Quarry LP bought a new position in shares of Akero Therapeutics in the 4th quarter valued at $83,000. Summit Investment Advisors Inc. lifted its stake in shares of Akero Therapeutics by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock valued at $197,000 after acquiring an additional 450 shares during the last quarter. Finally, Summit Financial Wealth Advisors LLC bought a new position in shares of Akero Therapeutics in the 3rd quarter valued at $205,000.

Analysts Set New Price Targets

AKRO has been the topic of several research reports. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $35.00 to $63.00 in a research report on Thursday, January 30th. Canaccord Genuity Group increased their price target on Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Citigroup increased their price target on Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. UBS Group increased their price target on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Finally, Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $76.29.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.